The global Endoscopic Retrograde Cholangiopancreatography (ERCP) market is growing rapidly, fueled by rising digestive disorders, a surge in the aging population, and increased adoption of endoscopy solutions for pancreatic and biliary diseases. The market was valued at USD 1.49 billion in 2024 and is expected to expand to USD 2.74 billion by 2033, registering a 7% CAGR between 2025 and 2033.

? Download Sample Report

Market Drivers

Rising Digestive and Chronic Biliary Disorders

A steady increase in chronic gastrointestinal conditions like Barrett's disease, Crohn's disease, GERD, pancreatitis, liver disease, and peptic ulcer disease is a key driver for ERCP demand. These conditions impact patients’ daily lives, fueling the need for advanced diagnostic and therapeutic procedures.

Increase in Benign Tumors

ERCP devices are increasingly used to diagnose and treat benign liver and pancreatic tumors, including adenomas, hemangiomas, and focal nodular hyperplasia (FNH). With the prevalence of such comorbidities, ERCP technology adoption is rising significantly.

Growing Elderly Population

The older population is more vulnerable to pancreatic cancer, biliary disorders, and benign tumors, creating a larger patient pool. Notably, 68.5% of pancreatic cancer cases in the U.S. occur in individuals over 65, making ERCP procedures vital for treatment and diagnosis.

Market Restraints

While demand is strong, the high costs of ERCP procedures and devices remain a restraint. Advanced devices like endoscopes, sphincterotomes, stents, and disposable accessories significantly add to treatment expenses. In fact, disposable equipment accounts for 27% of reimbursement in diagnostic ERCP and 68% in therapeutic ERCP, limiting overall adoption in cost-sensitive regions.

Market Opportunities

Increasing Global Awareness

As awareness about pancreatic, bile duct, and liver-related disorders rises, patients and healthcare providers are more inclined toward ERCP. Manufacturers are leveraging this trend, introducing next-gen ERCP devices with AI-powered and minimally invasive features, thus opening new growth opportunities worldwide.

Regional Insights

  • North America dominated the ERCP market in 2024 with a 49.56% share and is expected to reach USD 766.03 million by 2030. The U.S. leads in ERCP procedures due to advanced healthcare infrastructure and high adoption of imaging and endoscopy systems.

  • Europe stands as the second most lucrative market, with Germany holding the largest share owing to its advanced healthcare system and high pancreatic cancer prevalence.

  • Asia Pacific is witnessing rapid growth led by China, Japan, and India, driven by expanding medical infrastructure and universal healthcare policies.

  • Latin America and the Middle East & Africa are emerging markets with untapped opportunities, as awareness and access to ERCP procedures continue to expand.

Market Segmentation

  • By Product: Endoscopes, Endotherapy Devices, Imaging Systems, Energy Devices

  • By Application: Biliary Sphincterotomy, Biliary Dilatation, Biliary Stenting, Pancreatic Sphincterotomy, Pancreatic Duct Dilatation, Pancreatic Duct Stenting

  • By End-User: Hospitals & Clinics, Ambulatory Surgery Centers

  • By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

The endoscopes segment contributed the largest market share at 36.26% in 2024 and is expected to grow at 8.8% CAGR, driven by rising GI and biliary disorders. On the application side, biliary sphincterotomy leads the market at 8.1% CAGR, while pancreatic sphincterotomy is the fastest-growing due to the prevalence of pancreatic conditions. Among end-users, hospitals and clinics dominate with 7.8% CAGR, while ambulatory surgery centers are expanding fastest.

Key Players

The ERCP market is highly competitive, with leading players investing in innovation and strategic collaborations. Prominent companies include:

  • Olympus Corporation

  • Boston Scientific Corporation

  • Medtronic Plc

  • Fujifilm Holdings Corporation

  • Cook Group Incorporated

  • Conmed Corporation

  • Ambu Inc.

  • Telemed System Inc.

  • Becton, Dickinson and Company

Recent developments highlight innovation: in May 2025, Olympus launched OLYSENSE, an AI-powered endoscopy solution to support real-time decisions in ERCP. In April 2025, Medtronic partnered with Dragonfly™ Endoscopy to expand advanced pancreaticobiliary endoscopy solutions in the U.S.

Conclusion

The Endoscopic Retrograde Cholangiopancreatography (ERCP) market is on a robust growth trajectory, with increasing demand for minimally invasive solutions, technological advancements, and a rising aging population driving adoption. Despite high costs, the market presents strong opportunities for key players to innovate and expand globally.

About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision-making and ROI. Whether you are looking at business sectors in the next town or across continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

? Phone: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
? Email: sales@straitsresearch.com